Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
NIAID-supported research sheds light on why healthy people of the same age respond differently to vaccines.
Fauci, who has directed the National Institute of Allergy and Infectious Diseases since 1984, will step down in December.
The NIH and local researchers are collaborating to evaluate the antiviral drug TPOXX.
The small study found no evidence of delayed development of antibodies in participants who experienced rebound after taking Paxlovid.
The study, sponsored by the National Institutes of Health, will gather data on tecovirimat, or TPOXX.
Higher levels of viral antigens in the blood correlated with more severe disease.
Fauci led the U.S. HIV research effort for nearly 40 years before becoming the nation’s leading COVID-19 medical advisor.
What have we learned from the COVID-19 pandemic, and what’s the future of HIV vaccine research? Find out this #HVAD2022.
The HVTN 302 trial is evaluating experimental vaccines that deliver stabilized HIV spike proteins.
The removal of “AIDS” from the names of two CDC HIV agencies coincides with structural changes.
AVAC’s theme for HVAD 2021 is “HIV Vaccine Research: Building on Lessons from COVID.”
Abbott researchers found a high proportion of elite HIV controllers in the Democratic Republic of Congo, which could lead to cure insights.
The trial is evaluating an investigational vaccine from Janssen that may require only one shot.
The trial will enroll healthy volunteers to test the vaccine’s safety and ability to trigger an immune response.
Intravenous administration allowed the marginally effective BCG vaccination to work better in monkeys.
Structure-based candidate designed by NIAID scientists shows promise in early study.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.